Pharmacological interventions that increase myofiber size counter the functional decline of dystrophic muscles1,2. We show that deacetylase inhibitors increase the size of myofibers in dystrophin-deficient (MDX) and α-sarcoglycan (α-SG)–deficient mice by inducing the expression of the myostatin antagonist follistatin3 in satellite cells. Deacetylase inhibitor treatment conferred on dystrophic muscles resistance to contraction-coupled degeneration and alleviated both morphological and functional consequences of the primary genetic defect. These results provide a rationale for using deacetylase inhibitors in the pharmacological therapy of muscular dystrophies.
Engvall, E. & Wewer, U.M. FASEB J. 17, 1579–1584 (2003).
Zammit, P.S. & Partridge, T.A. Nat. Med. 8, 1355–1356 (2002).
Lee, S.J. Annu. Rev. Cell Dev. Biol. 20, 61–86 (2004).
Bogdanovich, S. et al. Nature 420, 418–421 (2002).
Wagner, K.R., McPherron, A.C., Winik, N. & Lee, S.J. Ann. Neurol. 52, 832–836 (2002).
Barton, E.R., Morris, L., Musaro, A., Rosenthal, N. & Sweeney, H.L. J. Cell Biol. 157, 137–148 (2002).
Iezzi, S., Cossu, G., Nervi, C., Sartorelli, V. & Puri, P.L. Proc. Natl. Acad. Sci. USA 99, 7757–7762 (2002).
Iezzi, S. et al. Dev. Cell 6, 673–684 (2004).
Emery, A.E. Lancet 359, 687–695 (2002).
Rafael, J.A., Tinsley, J.M., Potter, A.C., Deconinck, A.E. & Davies, K.E. Nat. Genet. 19, 79–82 (1998).
Duclos, F. et al. J. Cell Biol. 142, 1461–1471 (1998).
Parsons, S.A., Millay, D.P., Sargent, M.A., McNally, E.M. & Molkentin, J.D. Am. J. Pathol. 168, 1975–1985 (2006).
Puri, P.L. et al. Mol. Cell 8, 885–897 (2001).
Canettieri, G. et al. Nat. Struct. Biol. 10, 175–181 (2003).
Saito, A. et al. Proc. Natl. Acad. Sci. USA 96, 4592–4597 (1999).
We thank K.P. Campbell (Howard Hughes Medical Institute, University of Iowa) for providing α-SG–deficient mice, G. Cossu. and E. Engvall for critically reading the manuscript, and Alberto Bordonaro for the art work on figures. P.L.P is an assistant Telethon scientist at the Dulbecco Telethon Institute. This work was supported by a Telethon Special Grant to P.L.P. and R.B.; Muscular Dystrophy Association, Parent Project Organization and Compagnia San Paolo di Torino grants to P.L.P.; a European Union Grant and a Telethon Grant to M.C.C.; an Associazione Italiana Ricerca sul Cancro Regional Grant to C.G.; Cariplo Foundation and Italian Space Agency grants to R.B.; and grants from the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the US National Institutes of Health to M.D.P and V.S.
P.G. and C.S. are employees of the Istituto di Ricerca di Biologia Molecolare—Merck Research Laboratories.
Levels of histone acetylation in peripheral tissues of untreated and TSA, VPA or PHB-treated MDX mice. (PDF 199 kb)
Myogenic potential of satellite cells isolated from muscles of untreated and TSA, VPA or PHB-treated MDX mice. (PDF 1819 kb)
Improvement in muscle strength and function and levels of utrophin and dystrophin in untreated and TSA-treated MDX mice. (PDF 75 kb)
Distribution of fiber CSA and frequency histograms of single-fiber CSA in muscles from untreated and TSA-treated MDX mice. (PDF 78 kb)
Desmin-positive cells in muscle from untreated versus TSA-treated MDX mice. (PDF 55 kb)
Morphological and histological changes in muscles from untreated and TSA-treated MDX mice. (PDF 195 kb)
Myogenic potential of satellite cells isolated from muscles of α-SG–deficient mice untreated or TSA-treated; distribution of CSA and Azan Mallory staining of muscles from untreated and TSA-treated α-SG–deficient mice. (PDF 2836 kb)
Morphological and functional effects of MS 27-275 on MDX mice. (PDF 1144 kb)
About this article
Cite this article
Minetti, G., Colussi, C., Adami, R. et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 12, 1147–1150 (2006). https://doi.org/10.1038/nm1479
The FEBS Journal (2021)
Clinical Epigenetics (2021)
Current Neurology and Neuroscience Reports (2020)
Proceedings of the National Academy of Sciences (2020)
A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy
Skeletal Muscle (2020)